← Russell 3000 cross-section

NVCR NovoCure Ltd

Trailing twelve months to 2026-06-30 · as filed 2026-07-23, not restated
Healthcare

Scale

Market cap
$2.1bn
Revenue TTM
$699m
Net income TTM
$-149m
Free cash flow
$-25m
Composite score
38.7
Sector rank
#1612

Valuation

P / E
EV / EBITDA
EV / sales
2.9
FCF yield
-1.20%
Earnings yield vs 10-yr
-11.77pp

Earnings yield vs 10-yr compares what the business earns per pound invested against the 4.73% a 10-year US Treasury note pays for no equity risk. Negative means you are paying up front for growth not yet delivered.

Quality and growth

Net margin
-21.2%
EBITDA margin
ROE
-43.9%
ROIC
-63.2%
Revenue growth
10.9%

Insider activity, last 90 days

Net open-market
$-0.94m
Buyers
0
Sellers
8

Open-market purchases and sales only. Grants, option exercises, gifts and shares withheld for tax are excluded: they are how people are paid, not what they think.

What management said

Net revenues increased 16% to $183.6 million for the three months ending June 30, 2026 from $158.8 million for the same period in 2025. For the three months ended June 30, 2026 the net revenue increase primarily resulted from $16.1 million in growth from international markets and $8.7 million from the United States, collectively driven primarily by 18% active patient growth globally. In the quarter, there were $2.8 million in one-time revenue benefits included in the aforementioned market increases, consisting of $1.3 million from Germany related to approval rate increases and aged collections, $0.9 million from the United States from a lower annual deductible impact, and $0.6 million in Fra …NovoCure Ltd, 10-Q, period ended 2026-06-30, filed 2026-07-23

Read the full passage →